PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Galanthamine, extracted from N. pseudonarcissus, is a licensed treatment for Alzheimer's disease [PMID:33446764, 38453941]. Other isolated alkaloids, such as narcimatuline, have been evaluated as potential drugs for the same condition [PMID:31261031].
Narcissus pseudonarcissus lectin is listed as having anti-HIV activity [PMID:25569520].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 36744673 (2023) — Identification of haemanthamine as a phytotoxic alkaloid in Narcissus pseudonarcissus L. (Daffodil) emerging buds. · Natural product research
- 2.PMID: 25569520 (2015) — Lectins with anti-HIV activity: a review. · Molecules (Basel, Switzerland)
- 3.PMID: 39183765 (2024) — Complete plastome sequence of Narcissus pseudonarcissus L., one of the most iconic European plants. · Mitochondrial DNA. Part B, Resources
- 4.PMID: 23476470 (2013) — (2S,3R,4S,4aR)-2,3,4,7-Tetra-hydroxy-3,4,4a,5-tetra-hydro-[1,3]dioxolo[4,5-j]phenanthridin-6(2H)-one hemihydrate. · Acta crystallographica. Section E, Structure reports online
- 5.PMID: 36152726 (2022) — Structural analysis of unusual alkaloids isolated from Narcissus pseudonarcissus cv. Carlton.